Scandion is a biotechnology company. The company develops pharmaceuticals for the treatment of cancer containing drug-resistant cell clones. The leading product of the company, SCO-101, has shown to improve the effect of certain standard cancer treatments during preclinical studies. The head office of the company is located in Copenhagen.

Quotes for Scandion Oncology

Right Now

+/-
8.2
%
14,14%
Latest
66.2
High
66.8
Low
58.6
Volume
201 122
Turnover (SEK)
12 229 173
Value (MSEK)
1 261,3

Board

CEO

  • Nils Brünner

Chairman Of The Board

  • Peter Høngaard

Board

  • Annie Rasmussen
  • Bo Hansen
  • Carl Borrebäck
  • Christian Vinding Thomsen
  • Jørgen Bardenfleth
  • Thomas Feldthus

Videos

Largest Owners

Name Capital % Votes % Date
Saniona AB 9,99 9,99 2020-07-31
Jan Stenvang 7,30 7,30 2020-03-31
Avanza Pension 5,71 5,71 2020-03-31
Nils Brünner 5,65 5,65 2020-06-15
Nordnet Pensionsförsäkring 4,17 4,17 2020-03-31
Christian Tang Jespersen 2,75 2,75 2020-03-31
Göran Ofsén 1,97 1,97 2020-03-31
Jørgen Bardenfleth 1,85 1,85 2020-03-31
Cecél Kolz 1,84 1,84 2020-03-31
Kim Arvid Nielsen 1,57 1,57 2020-03-31
** Holdings by Modular Finance AB. Compiled and processed data from various sources, including Euroclear, Morningstar and the Swedish Financial Supervisory Authority.

Insider trading

Key Numbers

*Compiled data from Millistream

Upcoming reports

  • 2020-08-20 Delårsrapport 2020-Q2

  • 2020-11-19 Delårsrapport 2020-Q3